Northampton Electronic Collection of Theses and Research

Dystrophin quantification: biological and translational research implications

Anthony, K., Arechavala-Gomeza, V., Taylor, L. E., Vulin, A., Kaminoh, Y., Torelli, S., Feng, L., Janghra, N., Bonne, G., Beuvin, M., Barresi, R., Henderson, M., Laval, S., Lourbakos, A., Campion, G., Straub, V., Voit, T., Sewry, C. A., Morgan, J. E., Flanigan, K. M. and Muntoni, F. (2014) Dystrophin quantification: biological and translational research implications. Neurology. 83(22), pp. 2062-2069. 0028-3878.

Item Type: Article
Abstract: Objective: We formed a multi-institution collaboration in order to compare dystrophin quantification methods, reach a consensus on the most reliable method, and report its biological significance in the context of clinical trials. Methods: Five laboratories with expertise in dystrophin quantification performed a data-driven comparative analysis of a single reference set of normal and dystrophinopathy muscle biopsies using quantitative immunohistochemistry and Western blotting. We developed standardized protocols and assessed inter- and intralaboratory variability over a wide range of dystrophin expression levels. Results: Results from the different laboratories were highly concordant with minimal inter- and intralaboratory variability, particularly with quantitative immunohistochemistry. There was a good level of agreement between data generated by immunohistochemistry and Western blotting, although immunohistochemistry was more sensitive. Furthermore, mean dystrophin levels determined by alternative quantitative immunohistochemistry methods were highly comparable. Conclusions: Considering the biological function of dystrophin at the sarcolemma, our data indicate that the combined use of quantitative immunohistochemistry and Western blotting are reliable biochemical outcome measures for Duchenne muscular dystrophy clinical trials, and that standardized protocols can be comparable between competent laboratories. The methodology validated in our study will facilitate the development of experimental therapies focused on dystrophin production and their regulatory approval.
Subjects: Q Science > QH Natural history > QH426 Genetics > QH438.7 Human genetics
R Medicine > RC Internal medicine > RC925 Diseases of the musculoskeletal system > RC935.M7 Muscular dystrophy
Creators: Anthony, Karen, Arechavala-Gomeza, Virginia, Taylor, Laura E, Vulin, Adeline, Kaminoh, Yuuki, Torelli, Silvia, Feng, Lucy, Janghra, Narinder, Bonne, Gisele, Beuvin, Maud, Barresi, Rita, Henderson, Matt, Laval, Steven, Lourbakos, Afrodite, Campion, Giles, Straub, Volker, Voit, Thomas, Sewry, Caroline A, Morgan, Jennifer E, Flanigan, Kevin M and Muntoni, Francesco
Publisher: American Academy of Neurology
Faculties, Divisions and Institutes: University Faculties, Divisions and Research Centres - OLD > Research Centre > Institute of Health and Wellbeing > Ageing Research Centre
University Faculties, Divisions and Research Centres - OLD > Faculty of Health & Society > Sports, Exercise & Life Sciences
Faculties > Faculty of Health & Society > Sports, Exercise & Life Sciences
Research Centres > Centre for Health Sciences and Services
Research Centres > Centre for Physical Activity and Life Sciences
Date: 25 November 2014
Date Type: Publication
Page Range: pp. 2062-2069
Journal or Publication Title: Neurology
Volume: 83
Number: 22
Language: English
DOI: https://doi.org/10.​1212/​WNL.​0000000000001025
ISSN: 0028-3878
Status: Published / Disseminated
URI: http://nectar.northampton.ac.uk/id/eprint/8013

Actions (login required)

Edit Item Edit Item